“There is a huge unmet need here,” said Sarah Dolan, a consumer representative on the panel, the New York Times reported. Donanemab works targeting amyloid, a protein that can accumulate in the brains of patients.
►YOU MAY BE INTERESTED IN: Hereditary Transthyretin Amyloidosis: a rare disease that affects about 50 thousand people in the world
When will the new Alzheimer’s drug be approved?
The FDA regulated last year the Leqembi vaccine, from Eisai Inc. and Biogen. And if Eli Lilly’s donanemab is approved, the new treatment will be would become a potential rival and in the second medicine for the disease. The authorities must make a decision at the end of 2024.
Alzheimer’s: results of the study on the new drug
The drug slows cognitive decline and memory problems. In this regard, the Lilly study – which included 1,700 patients – ensures that effectiveness is equivalent to a few months of slow progression. However, they doubt whether Families and patients will notice the changes.
Health patient pill.jpg
They consider that the benefits of the new remedy against Alzheimer’s are greater than the possible contraindications
►YOU MAY BE INTERESTED IN: Prostate cancer: 13 thousand new cases are diagnosed per year in Argentina
The study found that patients who received monthly intravenous infusions of donanemab decreased by around 35% more slowly than those who received a placebo, according to Live Now Fox.
The main safety concern with donanemab was brain inflammation and bleeding, which turns out to be a common problem for all drugs targeting amyloid, This is how the aforementioned media reported.
